ClinicalTrials.gg
CompletedNCT01194570Updated Jan 10, 2024Results posted

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

A Phase 3 interventional study of Ocrelizumab and Placebo in Multiple Sclerosis, Primary Progressive, sponsored by Hoffmann-La Roche. Completed at 184 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
735
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.

Enrollment
4th of 10
735 · median 184
Started
2011
the only one that year
Phase 3
7 of 10
1 open now
Registered
1st of 10
by date
Lead sponsor
6 of 10
Hoffmann-La Roche

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 4th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 1st registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, or all of them as a file.
02

Study summary

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.

03

Conditions studied

  • Multiple Sclerosis, Primary Progressive
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary progressive multiple sclerosis (according to revised McDonald criteria)
  • EDSS at screening from 3 to 6.5 points
  • Disease duration from onset of MS symptoms less than (\<) 15 years if EDSS greater than (>) 5.0; \<10 years if EDSS greater than or equal to (>/=) 5.0
  • Sexually active male and female participants of must use two methods of throughout the study treatment phase and for 48 weeks after the last dose

Exclusion criteria

Exclusion Criteria:

  • History of relapsing remitting MS, secondary progressive, or progressive relapsing MS at screening
  • Inability to complete an MRI ( for MRI)
  • Known presence of other neurologic disorders
  • Known active infection or history of or presence of recurrent or chronic infection
  • History of cancer, including solid tumors and hematological (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)
  • Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
  • Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-cluster of differentiation 4 (CD4), cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
735 participants (actual)

Study arms

  • Experimental
    Placebo

    Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.

    Drug: Ocrelizumab · Other: Placebo

  • Placebo comparator
    Ocrelizumab 600 mg

    Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.

    Drug: Ocrelizumab

Interventions

  • Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.

  • OtherPlacebo

    Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.

06

What researchers measure

Primary outcomes

  1. Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period

    The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.

    Time frame: Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm

Secondary outcomes

  1. Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period

    The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.

    Time frame: Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm

  2. Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120

    Time frame: Baseline, Week 120

  3. Percent Change From Baseline in Total Volume of T2 Lesions at Week 120

    Time frame: From Baseline to Week 120

  4. Percent Change in Total Brain Volume From Week 24 to Week 120

    Time frame: From Week 24 to Week 120

  5. Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120

    The SF-36v2 is a 36-item, self- reported, generic measure of quality of life that has been widely used in multiple disease areas. It is composed of 8 health domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The PCS score was derived based on the SF-36 V2 User's Manual. Scoring for PCS involves (a) recoding item response values, (b) summing recoded response values for all items in a given scale to obtain the scale raw score, (c) transforming scale raw score to a 0-100 score. The PCS score was computed by (a) multiplying each health domain z score by a scale-specific physical factor score coefficient, (b) summing the resulting products, (c) converting the product total to T score. The total score ranges from 0-100, higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: From Baseline to Week 120

  6. Number of Participants With at Least One Adverse Event (AE)

    AEs included infusion related reactions (IRRs) and serious multiple sclerosis (MS) relapses, but excluded non-serious MS relapses.

    Time frame: From baseline to 9 years

07

Results

Posted Dec 26, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboOcrelizumab 600 mg
Started244488
Completed89218
Not completed155270
Withdrew: Adverse event2240
Withdrew: Death620
Withdrew: Lack of efficacy3233
Withdrew: Lost to follow-up415
Withdrew: Non-compliance22
Withdrew: Non-compliance with study drug22
Withdrew: Other1847
Withdrew: Physician decision1025
Withdrew: Protocol violation12
Withdrew: Study terminated by sponsor01
Withdrew: Withdrawal by subject5782
Withdrew: Pregnancy11

Outcome measures

PrimaryTime to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period

The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.

Time frame:
Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm
Reported as:
Median · weeks
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period
weeksPlaceboOcrelizumab 600 mg
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment PeriodNA (0 to NA)NA (0 to NA)
SecondaryTime to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period

The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.

Time frame:
Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm
Reported as:
Median · weeks
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period
weeksPlaceboOcrelizumab 600 mg
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment PeriodNA (0 to NA)NA (0 to NA)
SecondaryPercent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
Time frame:
Baseline, Week 120
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
percent changePlaceboOcrelizumab 600 mg
Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 12055.097 (39.855 to 71.999)38.933 (29.222 to 49.374)
Statistical analysis
  • Placebo vs Ocrelizumab 600 mg · Ranked ANCOVA · p = 0.0404 (P-value from a ranked ANCOVA on Percent Change from BL adjusting for rank of BL 25-Foot Timed Walk (25-FTW), Geographical Region (US vs ROW) and Age (\<=45, \> 45 years); missing observations imputed with LOCF.) · Relative reduction (%): 29.337 · 95% CI -1.618 to 51.456Relative reduction was calculated as -Relative change = - (Ocrelizumab response-Placebo response)/Placebo response\*100%. The 95% CI for relative reduction was obtained using the Bootstrap method.
SecondaryPercent Change From Baseline in Total Volume of T2 Lesions at Week 120
Time frame:
From Baseline to Week 120
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Volume of T2 Lesions at Week 120
percent changePlaceboOcrelizumab 600 mg
Percent Change From Baseline in Total Volume of T2 Lesions at Week 1207.426 (4.967 to 9.942)-3.366 (-4.987 to -1.718)
Statistical analysis
  • Placebo vs Ocrelizumab 600 mg · Ranked ANCOVA · p = < 0.0001 (P-value is from ranked ANCOVA on Percent Change from BL adjusting for rank of BL T2 lesion volume, Geographical Region (US vs ROW) and Age (\<=45, \> 45 years); missing observations imputed with LOCF.) · Ratio of adjusted geometric means: 0.9 · 95% CI 0.876 to 0.924
SecondaryPercent Change in Total Brain Volume From Week 24 to Week 120
Time frame:
From Week 24 to Week 120
Reported as:
Least squares mean · percent change
Percent Change in Total Brain Volume From Week 24 to Week 120
percent changePlaceboOcrelizumab 600 mg
Percent Change in Total Brain Volume From Week 24 to Week 120-1.093 (-1.236 to -0.951)-0.902 (-1.004 to -0.799)
Statistical analysis
  • Placebo vs Ocrelizumab 600 mg · MMRM · p = 0.0206 · Relative reduction (%): 17.475 · 95% CI 3.206 to 29.251Relative reduction was calculated as -Relative change = - (Ocrelizumab response-Placebo response)/Placebo response\*100%. The 95% CI for relative reduction was obtained using the Bootstrap method.
SecondaryChange in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120

The SF-36v2 is a 36-item, self- reported, generic measure of quality of life that has been widely used in multiple disease areas. It is composed of 8 health domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The PCS score was derived based on the SF-36 V2 User's Manual. Scoring for PCS involves (a) recoding item response values, (b) summing recoded response values for all items in a given scale to obtain the scale raw score, (c) transforming scale raw score to a 0-100 score. The PCS score was computed by (a) multiplying each health domain z score by a scale-specific physical factor score coefficient, (b) summing the resulting products, (c) converting the product total to T score. The total score ranges from 0-100, higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame:
From Baseline to Week 120
Reported as:
Least squares mean · units on a scale
Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120
units on a scalePlaceboOcrelizumab 600 mg
Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120-1.108 (-2.394 to 0.177)-0.731 (-1.655 to 0.193)
Statistical analysis
  • Placebo vs Ocrelizumab 600 mg · MMRM · p = 0.6034 · Difference in adjusted means: 0.377 · 95% CI -1.048 to 1.802Difference in adjusted mean was calculated as Ocrelizumab SF-36 Physical Component Summary Score - Placebo SF-36 Physical Component Summary Score.
SecondaryNumber of Participants With at Least One Adverse Event (AE)

AEs included infusion related reactions (IRRs) and serious multiple sclerosis (MS) relapses, but excluded non-serious MS relapses.

Time frame:
From baseline to 9 years
Reported as:
Number · Participants
Number of Participants With at Least One Adverse Event (AE)
ParticipantsPlaceboOcrelizumab 600 mgPlacebo (Open Label Extension)Ocrelizumab (Open Label Extension)
Serious Adverse Events539959167
Adverse Events215462148354

Adverse events

Collected over Baseline up to 615 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB PLACEBO3/239 (1.3%)58/239 (24.3%)175/239 (73.2%)
DB OCRELIZUMAB3/486 (0.6%)104/486 (21.4%)400/486 (82.3%)
OLE PLACEBO4/158 (2.5%)59/158 (37.3%)134/158 (84.8%)
OLE OCRELIZUMAB19/369 (5.1%)167/369 (45.3%)318/369 (86.2%)
Most frequent serious events
Showing 10 of 330
Most frequent serious events
EventDB PLACEBODB OCRELIZUMABOLE PLACEBOOLE OCRELIZUMAB
COVID-19 PNEUMONIAInfections and infestations0/2390/4865/15831/369
URINARY TRACT INFECTIONInfections and infestations4/2394/4867/15820/369
PNEUMONIAInfections and infestations3/2396/4863/15817/369
COVID-19Infections and infestations0/2390/4862/15812/369
SEPSISInfections and infestations0/2390/4862/1587/369
UROSEPSISInfections and infestations2/2392/4862/1587/369
CELLULITISInfections and infestations0/2393/4862/1585/369
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/2390/4861/1585/369
APPENDICITISInfections and infestations0/2392/4862/1583/369
INVASIVE DUCTAL BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2392/4862/1580/369
Most frequent other events
Showing 10 of 33
Most frequent other events
EventDB PLACEBODB OCRELIZUMABOLE PLACEBOOLE OCRELIZUMAB
INFUSION RELATED REACTIONInjury, poisoning and procedural complications61/239194/48640/15856/369
URINARY TRACT INFECTIONInfections and infestations57/239103/48644/158127/369
NASOPHARYNGITISInfections and infestations63/239117/48648/158100/369
COVID-19Infections and infestations0/2390/48621/15876/369
PNEUMONIAInfections and infestations0/2390/48621/15876/369
BACK PAINMusculoskeletal and connective tissue disorders38/23959/48623/15854/369
ARTHRALGIAMusculoskeletal and connective tissue disorders30/23956/48623/15857/369
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations14/23960/48614/15856/369
HEADACHENervous system disorders31/23968/48615/15841/369
DEPRESSIONPsychiatric disorders31/23934/4869/15823/369

Baseline characteristics

Analysis was performed on intent to treat (ITT) population which included all randomized participants in the study.

Age, Categorical
Age, Categorical(Participants)PlaceboOcrelizumab 600 mgTotal
<=18 years000
Between 18 and 65 years244488732
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboOcrelizumab 600 mgTotal
Mean44.4 ± 8.344.7 ± 7.944.6 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOcrelizumab 600 mgTotal
Female124237361
Male120251371
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOcrelizumab 600 mgTotal
Hispanic or Latino143246
Not Hispanic or Latino206385591
Unknown or Not Reported247195
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOcrelizumab 600 mgTotal
American Indian or Alaska Native055
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5914
White235454689
More than one race000
Unknown or Not Reported42024
08

Study locations

184 sites
  • Phoenix Neurological Associates Ltd
    Phoenix, Arizona 85006, United States
  • Barrow Neurology Clinic
    Phoenix, Arizona 85013, United States
  • Mayo Clinic- Scottsdale
    Scottsdale, Arizona 85259, United States
  • Arizona Neuroscience Research LLC
    Phoenix, Arkansas 85032-2181, United States
  • Sutter East Bay Medical Foundation
    Berkeley, California 94705, United States
  • MS Center of Southern California
    Newport Beach, California 92663, United States
  • Univ of CA Davis Med Ctr; Neurology
    Sacramento, California 95817, United States
  • Univ of CA San Francisco; Department of Neurology
    San Francisco, California 94143, United States
  • University of Colorado; Anschutz Medical Campus Department of Neurology
    Aurora, Colorado 80045, United States
  • University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center
    Miami, Florida 33136, United States
  • Vero Beach Neurology and Research Institute
    Vero Beach, Florida 32960, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • MidAmerica Neuroscience Institute
    Prairie Village, Kansas 66206, United States
  • Wayne State University; Department of Neurology
    Detroit, Michigan 48201, United States
  • Henry Ford Health System; Neurology & Neurosurgery
    Detroit, Michigan 48202, United States
  • Michigan Institute for Neurological Disorders
    Farmington Hills, Michigan 48334, United States
  • University of Minnesota; Clin. Neuro Research Unit
    Minneapolis, Minnesota 55414, United States
  • Washington University School of Medicine; Department of Neurology
    Saint Louis, Missouri 63110, United States
  • Holy Name Hospital
    Teaneck, New Jersey 07666, United States
  • University of New Mexico; MS Specialty Clinic
    Albuquerque, New Mexico 87131, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Weill Medical College of Cornell University; Judith Jaffe MS Ctr
    New York, New York 10021, United States
  • Mount Sinai School of Medicine; Neurology
    New York, New York 10029, United States
  • Comprehensive MS Care Center at South Shore Neurologic Assoc.
    Patchogue, New York 11772, United States
  • Neurology Assoc of Stony Brook
    Stony Brook, New York 11794, United States
  • Carolinas Medical Center; Ms Center
    Charlotte, North Carolina 28207, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607-6520, United States
  • The Ohio State University Wexner Medical Center; Department of Neurology
    Columbus, Ohio 43221, United States
  • Oklahoma Medical Research Foundation; MS Center of Excellence
    Oklahoma City, Oklahoma 73104, United States
  • Trustees of the University of Pennsylvania; Neurology
    Philadelphia, Pennsylvania 19104, United States
  • The Neurology Foundation, Inc.
    Providence, Rhode Island 02905, United States
  • Neurology Clinic PC
    Cordova, Tennessee 38018, United States
  • University of Texas Southwestern
    Dallas, Texas 75390-8897, United States
  • Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology
    Houston, Texas 77030, United States
  • Neurological Associates, Inc.
    Richmond, Virginia 23229, United States
  • Swedish Neuroscience Institute; Multiple Sclerosis Center
    Seattle, Washington 98122, United States
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research
    Fitzroy, Victoria 3065, Australia
  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
    Innsbruck, 6020, Austria
  • Kepler Universitätsklinikum GmbH - Neuromed Campus; Neurologie
    Linz, 4020, Austria
  • Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie
    Linz, 4021, Austria
  • Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie
    Salzburg, 5020, Austria
  • Medizinische Universitat Wien Medical University of Vienna
    Wien, 1090, Austria
  • CHU Tivoli
    La Louvière, 7100, Belgium
  • AZ Alma vzw (Sijsele)
    Sijsele, 8340, Belgium
  • Hospital das Clinicas - UFG;Reumatologia
    Goiania, GO 74653-050, Brazil
  • Santa Casa de Misericordia; de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Hospital Universitario Clementino Fraga Filho - UFRJ
    Rio de Janeiro, RJ 21941-913, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Shat Np Sveti Naum; 3Rd Clinic of Neurology
    Sofia, 1113, Bulgaria
  • Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
    Sofia, 1309, Bulgaria
  • Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
  • University of British Columbia UBC Hospital; Multiple Sclerosis (MS) Clinic - Vancouver
    Vancouver, British Columbia V6T 1Z3, Canada
  • Health Sciences Centre
    Winnipeg, Manitoba R8A 1R9, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • St. Michael'S Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Recherche Sepmus Inc.
    Greenfield Park, Quebec J4V 2J2, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • Fakultni nemocnice Brno; Interni kardiologicka klinika
    Brno, 625 00, Czechia
  • Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika
    Praha 2, 128 08, Czechia
  • Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni
    Teplice, 415 29, Czechia
  • Helsingin yliopistollinen keskussairaala
    Helsinki, 00290, Finland
  • Tampereen yliopisto; Kliinisen lääketieteen laitos, Neurologian yksikkö
    Tampere, 33520, Finland
  • Turku University Central Hospital; Pharmacy
    Turku, 20520, Finland
  • Groupe Hospitalier Pellegrin; Service de neurochirurgie B
    Bordeaux, 33076, France
  • Hopital Neurologique et Neurochirurgical Pierre Wertheimer; Service de Neurologie A
    Bron, 69677, France
  • Hopital Cote De Nacre; Unite Neurologie Generale
    Caen, 14033, France
  • Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B
    Clermont-Ferrand, 63003, France
  • Hopital Roger Salengro Service de Neurologie
    Lille, France
  • CHU de la Timone - Hopital d Adultes; Service de Neurologie
    Marseille, 13005, France
  • Hopital Gui de Chauliac; Neurologie
    Montpellier, 34295, France
  • CHRU Nancy; Service de neurologie
    Nancy, 54035, France
  • Hôpital Guillaume et René Laënnec; Service Neurologie
    Nantes, 44805, France
  • Hôpital Pasteur; Service de Neurologie
    Nice, 06002, France
  • Groupe Hospitalo-Universitaire Caremeau; Service Neurologie
    Nimes, 30029, France
  • Fondation Rothschild; Service de Neurologie
    Paris, 75019, France
  • Groupe Hospitalier Pitié- Salpétrière; Service Neurologie
    Paris, 75651, France
  • Hôpital de Poissy; Service neurologie
    Poissy, 78300, France
  • Hôpital Maison Blanche; Service de Neurologie
    Reims, 51092, France
  • Chu De Strasbourg; Hopital Civil
    Strasbourg, 67091, France
  • Hopital Purpan; Fédération de neurologie
    Toulouse, 31059, France
  • Klinikum Bayreuth GmbH; Neurologische Klinik
    Bayreuth, 95445, Germany
  • Marianne-Strauß-Klinik; Behandlung Kempfen für Multip Sklero Kranke gemeinnütz GmbH
    Berg, 82335, Germany
  • Charite - Universitatsmedizin Berlin; Klinik fur Neurologie
    Berlin, 10117, Germany
  • Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie
    Berlin, 13347, Germany
  • Berufsgenossenschaftliches Uni-Klinikum Bergmannsheil GmbH
    Bochum, 44789, Germany
  • Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Neurologie
    Dresden, 01307, Germany
  • Heinrich Heine Universität Düsseldorf; Neurologische Klinik
    Düsseldorf, 40225, Germany
  • Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie
    Frankfurt am Main, 60528, Germany
  • Universitätsklinikum Gießen und Marburg GmbH; Neurologie
    Gießen, 35392, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Kliniken der Stadt Koln gGmbH
    Koln, 51109, Germany
  • Universität Leipzig; Innere Medizin, Neurologie, Dermatologie
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    Munchen, 81675, Germany
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Medizinische Einrichtungen des Bezirks Oberpfalz GmbH; Neurologie
    Regensburg, 93053, Germany
  • Universitätsklinikum Tübingen, Zentrum für Neurologie
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm; Klinik für Neurologie
    Ulm, 89081, Germany
  • DKD Helios Klinik (Deutsche Klinik für Diagnostik GmbH)
    Wiesbaden, 65191, Germany

Showing the first 100 of 184 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, Kappos L, Kolind S, Bonati U, Magon S, van Beek J, Koendgen H, Bortolami O, Bernasconi C, Gaetano L, Traboulsee A. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler. 2022 Oct;28(12):1927-1936. doi: 10.1177/13524585221097561. Epub 2022 Jun 7. PubMed 35672926 ↗
  • Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Kubala Havrdova E, Grand'Maison F, Prat A, Girard M, Hupperts R, Onofrj M, Lugaresi A, Taylor B; MSBase Study Group; Giovannoni G, Kappos L, Hauser SL, Montalban X, Craveiro L, Freitas R, Model F, Overell J, Muros-Le Rouzic E, Sauter A, Wang Q, Wormser D, Wolinsky JS. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. Eur J Neurol. 2022 Apr;29(4):1082-1090. doi: 10.1111/ene.14824. Epub 2021 May 6. PubMed 33724638 ↗
  • Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29. Erratum In: Lancet Neurol. 2021 Jan;20(1):e1. doi: 10.1016/S1474-4422(20)30437-3. PubMed 33129442 ↗
  • Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12. PubMed 30415593 ↗
  • Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313. PubMed 30155979 ↗
  • Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. PubMed 28002688 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jul 2015, 52 months.

Results were first posted in Dec 2017, 2 years 5 months after primary completion. A results delay was requested in Oct 2016.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 52 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2010
First posted
Sep 3, 2010
StartActual
Mar 2, 2011
Primary completionActual
Jul 23, 2015
CompletionActual
Dec 31, 2022
Results delay requested
Oct 14, 2016
Results first posted
Dec 26, 2017
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01194570
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 3, 2010
Start date
Mar 2, 2011
Primary completion
Jul 23, 2015
Completion
Dec 31, 2022
Results posted
Dec 26, 2017
Last update
Jan 10, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion